Repligen (NASDAQ:RGEN) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Repligen (NASDAQ:RGEN) announced its earnings results on Thursday. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03, Zacks reports. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen updated its FY 2025 guidance to 1.670-1.760 EPS.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $162.67 on Friday. Repligen has a 12 month low of $113.50 and a 12 month high of $203.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The business has a fifty day simple moving average of $155.17 and a 200-day simple moving average of $148.81.

Analyst Upgrades and Downgrades

Several analysts have commented on RGEN shares. Wolfe Research initiated coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Canaccord Genuity Group started coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. HC Wainwright lowered their price objective on Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Finally, TD Cowen initiated coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price target for the company. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $182.91.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.